Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Indian Firm Continuing Talks With FDA For Complex ANDA Product

 
• By Dean Rudge
Sales growth concept
GxAbraxane is one of several assets set to boost Cipla's top line • Source: Alamy

More from Business

More from Generics Bulletin